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Alzheimer’s disease is a neurodegenerative condition associated with neurofibrillary tangles and cortical 3 
deposition of amyloid plaques. Clinical presentation of the disease involves manifestations such as memory 4 
loss, cognitive decline and dementia with some of the earliest reported deficits being episodic memory 5 
impairment and olfactory dysfunction. Current diagnostic approaches rely on autopsy characterization of gross 6 
brain pathology, or brain imaging of biomarkers late in the disease course. The aim of this literature review is 7 
to identify and compare novel blood-based biomarkers with the potential of making an earlier clinical diagnosis 8 
of Alzheimer’s disease. Utilizing such techniques may allow for earlier therapeutic intervention, reduction of 9 
disability and enhancement of patients’ quality of life. Literature review and analysis was performed by 10 
screening the PubMed database for relevant studies between July 1, 2014 and December 31, 2019. Sixteen 11 
studies were reviewed with biomarker candidates categorized under microRNAs (miRNAs), auto-antibodies, 12 
other blood-based proteins or circulating nucleic acids. Three biomarker candidates – serum neurofilament 13 
light chain, plasma β-secretase 1 activity and a panel of three miRNAs (miR-135a/193b/384) – reported 14 
statistically significant differences in testing between patients and controls, with high discriminative potential 15 
and high statistical power. In conclusion, certain blood biomarkers have shown promising results with high 16 
sensitivity and specificity, high discriminative potential for Alzheimer’s disease early in its progression, and 17 
statistically significant results in larger study samples. Utilization of such diagnostic biomarkers could increase 18 
the efficacy of making an earlier clinical diagnosis of Alzheimer’s disease. 19 
 20 
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Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases, first described by German 3 
psychiatrist Alois Alzheimer in 1906, and currently affecting millions of people on a global scale.1 4 
Approximately 5.8 million Americans are diagnosed with AD and by 2050 this number is expected to increase 5 
to 13.8 million.2 An important characteristic to note is the propensity of the disease to cause dementia – an 6 
acquired syndrome resulting in declining memory, executive function and cognitive ability, sufficient to cause 7 
interference with daily life and functioning. Globally, an estimated 50 million people have dementia, of which 8 
60-70% of cases are due to AD.3 Total costs of health care and services in 2015 for all individuals with 9 
Alzheimer’s or other dementias worldwide were estimated at US $818 billion, placing a substantial financial 10 
burden on many families.3 11 
 12 
The best known risk factor for AD is increasing age, especially with people aged 65 and older, resulting in a 13 
subset of AD known as sporadic or late-onset Alzheimer’s disease (LOAD). Old age, however, is not the 14 
defining requisite of the disease, as there is also a younger-onset (before age 65) pattern, referred to as early-15 
onset Alzheimer’s disease (EOAD), with about 13% associated with particular genes and familial inheritance.4 16 
One of the earliest cognitive deficits of either form of AD is episodic memory impairment, which presents as a 17 
reduced ability to recall events specific to a place and time.5 As the disease progresses, it manifests as 18 
dementia, due to involvement of cortical association areas, with clinical manifestations including progressive 19 
memory impairment, deficits in executive functions and semantic memory, disorientation, behavioral changes 20 
and mood alterations. The diagnosis of AD is based on both clinical manifestations and gross morphological 21 
changes due to disease pathology and neurodegeneration in the brain. Consequently, AD (LOAD specifically) 22 
is detected quite late in the disease course, along with histopathological confirmation of neurodegeneration 23 
observable on autopsy, or in rare cases, biopsy.6 24 
 25 
Since their discovery, neurofibrillary tangles (NFTs) and senile amyloid plaques have been the hallmark 26 
neuropathological features of AD.7 Amyloid precursor protein (APP) is a highly conserved and integral 27 
membrane protein found in various tissues and is highly concentrated in neural synapses.5 The sequential 28 
cleavage of APP by the enzymes β-secretase 1 (BACE1) and γ-secretase results in the formation of amyloid-29 
β (Aβ). The pathogenesis of AD is hypothesized by some groups to be linked to an imbalance between 30 
amyloid-β (Aβ) production and clearance, resulting in the aggregation of Aβ predominantly as Aβ42 and Aβ40, 31 
which contribute to amyloid plaques and angiopathy respectively, although Aβ40 can also play a role in 32 
plaque formation.8 The neurotoxicity of these plaques plays an important part in the preclinical phase of the 33 
disease.5 Other groups hypothesize that the causative neuropathology of AD is related to tau, a protein 34 
expressed in neurons that plays an important role in the regulation of microtubules and their stability within 35 
axons. The functioning of tau is in turn regulated by several post-translational modifications to the protein 36 
itself. The most significant modification involves phosphorylation of serine and threonine residues, which can 37 
also result in hyperphosphorylation of tau protein, leading to the formation of NFTs.5 38 
 39 
The strongest predisposing risk factor for LOAD is the genotype of Apolipoprotein E (APOE), a gene that 40 
encodes the ε2, ε3 and ε4 alleles. Of the three alleles, ε4 is inversely correlated with age of disease onset, as 41 
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increased expression results in an earlier than usual disease onset. Additionally, one APOEε4 allele and two 1 
APOEε4 alleles are associated with a 3x and 12x increase in risk of developing LOAD, respectively.9 The 2 
APOEε4 protein is an important regulator of lipoprotein metabolism and plays a significant role in the 3 
aggregation of Aβ as well as its clearance from the central nervous system. These underlying genetic 4 
changes ultimately give rise to the gross morphological features seen in the brains of patients with AD. 5 
 6 
Autopsy findings in brains from AD patients are grossly characterized by widespread cortical atrophy, 7 
especially involving the entorhinal cortex (anterior portion of the parahippocampal gyrus) and the neighboring 8 
hippocampal formation.10 The neuronal atrophic changes in these and other densely cholinergic areas are 9 
subsequently accompanied by sulcal widening and gyri narrowing in much of the cerebral cortex. The 10 
extensive cortical neuronal atrophy can also give rise to ventriculomegaly and hydrocephalus ex vacuo.11 11 
Microscopic examination of the affected tissue generally reveals senile plaques composed of Aβ as well as 12 
NFTs of hyperphosphorylated tau, as discussed. The disease is also characterized by whole brain reduction 13 
in acetylcholine while levels of other neurotransmitters remain relatively unaffected until late stages.11 14 
 15 
The underlying pathology of AD is known to begin much earlier than the onset of clinical manifestations. As 16 
such, a set of new criteria for the staging of AD was proposed by the National Institute of Aging and 17 
Alzheimer’s Association in 2012. The criteria define three distinct stages of AD: preclinical AD, mild cognitive 18 
impairment (MCI) and AD dementia.12 The preclinical and early MCI stages would be those where AD 19 
pathology and possible memory deficits should be present, but cognition would be intact, and as such, 20 
disease-modifying therapeutics would be most efficacious in these stages.  21 
 22 
Biomarkers have classically been used to characterize the pathology seen in several conditions including AD. 23 
The historic and most widely used biomarkers for AD are Aβ and tau, with AD patients having lower levels of 24 
Aβ in cerebrospinal fluid (CSF) due to accumulation in plaques, and higher levels of CSF tau.13 When looking 25 
at these markers in blood, studies have reported marginally lower plasma Aβ42 levels,14 and significantly 26 
higher plasma tau levels in AD patients as compared to control subjects.15 Neuropathological markers such as 27 
Aβ and tau can be directly visualized by biopsy and immunohistochemistry. These diagnostic techniques are 28 
largely invasive and mostly utilized on autopsy or late during the disease course, once the patient develops 29 
cognitive decline and clinical interventions are warranted. Accumulation of Aβ in the brain is a very early 30 
event, starting at least a decade before symptoms appear. Well-established Aβ-biomarkers, such as Aβ-31 
binding ligands for in-vivo positron imaging tomography (PET) imaging, can be utilized to measure the Aβ 32 
deposition.16 Imaging methods like PET, however, may be prohibitively expensive. Nevertheless, there is 33 
ongoing research investigating plasma Aβ42/Aβ40, with a recent study providing Class II evidence that 34 
Aβ42/Aβ40 levels when combined with APOE ε4 status and age, can accurately determine amyloid PET 35 
status in cognitively normal individuals.17 36 
 37 
The involvement of olfactory dysfunction early in the disease course of AD has been reported as early as 38 
1974 and may possibly be one of the earliest manifestations of the disease.18 The olfactory dysfunction seen 39 
in AD is associated with Aβ and NFT deposition in the olfactory bulb – the olfactory pathway’s very first 40 
synaptic relay.19 Early AD also affects portions of the olfactory cortex, and degeneration is known to be more 41 
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pronounced in the left hemisphere of patients with AD. Techniques involving simple olfactory tests have been 1 
studied in the past, using stimuli such as a peanut butter. It has been previously reported that such a test can 2 
discriminate AD patients from those with MCI and controls with a sensitivity of 100% and specificity of 92%.20 3 
 4 
Aside from Aβ and tau, there have been advances in the field of other blood-based biomarkers capable of 5 
discriminating between those with MCI and healthy controls, and several studies of novel biomarkers 6 
detectable in serum and plasma have emerged. Preclinical diagnosis of AD by using such biomarkers, can 7 
allow for early therapeutic interventions and new clinical trials, which may result in reduced disability and a 8 
better quality of life for patients. This literature review study explores the efficacy of utilizing novel blood-based 9 




Search Strategy 14 
The scientific literature used in this review was selected through screening of literature pertaining to the topic 15 
of interest by searching the PubMed database. The initial search parameters included combinations of 16 
Medical Subject Headings “Alzheimer’s disease” or “Alzheimer disease” along with the words “biomarkers”, 17 
“serum” and “plasma”. This initial search yielded 372 articles. Only studies published in English and involving 18 
humans were considered for inclusion. A recent systematic review and meta-analysis on CSF and blood 19 
biomarkers for AD included studies from July 1, 1984 and June 30, 2014. Carrying forward from then, studies 20 
published between July 1, 2014 and December 31, 2019 were considered for inclusion in this review of novel 21 
blood-based AD biomarkers. Review articles were filtered out from the search. This yielded 162 articles for 22 
further screening and study selection. The abstracts of these articles were thoroughly reviewed to determine 23 
eligibility. 24 
 25 
Eligibility Criteria 26 
Studies were selected by analyzing the abstracts of the studies for relevancy to the topic of interest. Given the 27 
focus of the review is on biomarkers with the potential to detect AD earlier in the disease course, studies not 28 
including mild AD or MCI patients in the study sample were excluded. Studies that focused on the ability of 29 
biomarkers to differentiate either AD patients, MCI patients, or AD and MCI patients from cognitively healthy 30 
individuals were selected. Studies that focused on the ability of biomarkers to discriminate between either AD 31 
patients, MCI patients, or AD and MCI patients from patients with other neurodegenerative conditions (such 32 
as Parkinson’s disease, vascular dementia, etc.), were excluded. Studies that examined the utility of novel 33 
biomarkers for the initial diagnosis of MCI, or AD, or MCI and AD were selected; those studies in this subset 34 
examining only other effects of biomarker utility, such as AD progression or response to treatment, and not 35 
initial diagnosis, were also excluded. After thoroughly reviewing article abstracts and applying these eligibility 36 
criteria, sixteen articles were selected. 37 
 38 
Data Extraction 39 
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The following information was extracted from selected studies and analyzed for this review: Study objectives, 1 





The sixteen reviewed studies investigated several different blood-based biomarker candidates for detecting 7 
AD earlier in the disease course. These candidates included microRNAs (miRNAs), autoantibodies, other 8 
proteins and circulating nucleic acids.  9 
 10 
microRNA levels 11 
Five studies, summarized in Table 1, focused on investigating the utility of miRNAs as biomarkers for earlier 12 
detection of AD.21-25 Four studies included patients with AD and MCI, and one study included patients with 13 
mild and moderate AD. All five studies utilized quantitative real time polymerase chain reaction for 14 
quantification of differentially expressed miRNAs. Levels of seven miRNAs (miR-135a, -384, -4668-5p, -483-15 
5p, -200a-3p, -93 and 146a) were found to be significantly higher in MCI patients as compared to controls. 16 
Levels of three other miRNAs (miR-193b, -222 and-143) were found to be significantly lower in patients with 17 
MCI or mild AD as compared to controls.  18 
 19 
Serum autoantibodies 20 
Two studies, summarized in Table 2, focused on investigating serum autoantibodies as diagnostic biomarkers 21 
for early detection of AD. The studies included patients with MCI or mild AD and utilized the enzyme-linked 22 
immunosorbent assay technique for antibody detection. Levels of anti-phosphatidylserine-dependent antibody 23 
(aPSd), anti-phosphatidylethanolamine-dependent antibody (aPEd) and anti-phosphatidylcholine-independent 24 
antibody (aPCi) were found to be significantly elevated in the serum of MCI patients as compared to 25 
controls.26 Antibodies against the angiotensin 2 type 1 receptor (anti-ATR1) were found to be significantly 26 
higher in mild AD patients without hypertension or diabetes.27  27 
 28 
Other blood-based proteins 29 
Eight studies, summarized in Table 3, focused on other blood-based proteins as biomarkers for earlier 30 
detection of AD. Dynamics of neurofilament light chain (NfL) have been found to predict neurodegeneration 31 
and clinical progression in presymptomatic AD.28 Serum NfL rates of change were significantly elevated in 32 
individuals carrying highly penetrant autosomal-dominant mutations in the amyloid beta precursor protein 33 
(APP), presenilin 1 (PSEN1) or presenilin 2 (PSEN2) genes, as compared to non-carriers. Furthermore, the 34 
rates of change of serum NfL in symptomatic mutation carriers were significantly associated with rates of 35 
cortical thinning in the precuneus.28  36 
 37 
Keratin type-2 expression, neuronal pentraxin 1 (NP1) levels and BACE1 activity were all found to be 38 
significantly elevated in MCI patients compared to controls.29-31 Angiotensin converting enzyme (ACE) serum 39 
activity was significantly higher in AD patients as compared to controls and MCI patients, but no significant 40 
difference existed between MCI patients and controls.32 Levels of soluble endothelial protein C receptor 41 
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(sEPCR) and Galectin-3 (Gal-3) were found to be significantly elevated in AD patients compared to controls, 1 
but no significant difference existed between MCI patients and controls.33,34 Expression of albumin was 2 
significantly decreased in MCI patients compared to controls.29  3 
 4 
Mean exosomal levels of extracted phospho-serine-type 1 insulin receptor substrate (P-S312-IRS-1) were 5 
significantly higher in early AD patients compared to controls.35 Mean exosomal levels of extracted phospho-6 
tyrosine-type 1 insulin receptor substrate (P-panY-IRS-1) were significantly lower in early AD patients 7 
compared to controls. The ratio of P-S312-IRS-1 to P-panY-IRS-1 (Insulin Resistance Index, R) was 8 
significantly higher in early AD patients. Insulin resistance reflected by R values could accurately predict 9 
development of AD up to 10 years prior to symptom onset.35  10 
 11 
Circulating Nucleic Acids 12 
One study, summarized in Table 4, focused on circulating nucleic acids (CNAs) as diagnostic biomarkers for 13 
AD. Patients with probable-AD were found to have higher CNA concentrations compared to controls. DNA 14 
methylation of the LHX2 gene was also found to be significantly higher in these patients.36 Furthermore, upon 15 
subclassifying probable-AD patients by MMSE scores, CNA concentrations peaked in the MCI subclass 16 




A novel biomarker, which is sensitive and specific to the development of AD pathology would be an ideal 21 
candidate for the preclinical detection of the disease. As such, an ideal biomarker for early AD diagnosis 22 
should distinguish between cognitively normal elderly controls and patients with MCI, with great accuracy, 23 
sensitivity and specificity. The ideal biomarker should also reasonably predict conversion from cognitively 24 
healthy individuals to MCI, and progression from MCI to AD. For each biomarker reviewed, the discriminative 25 
potential quantified by measures of diagnostic accuracy, if available, is summarized in Table 5. 26 
 27 
Over the last decade, researchers have focused on developing non-invasive tests for AD based on detection 28 
of miRNAs in the blood. These non-coding, small nucleotide molecules have been found to be differentially 29 
regulated in the blood, CSF and even brain tissue of patients with AD.37 The panel of three miRNAs (miR-30 
135a, -193b, -384) studied by Yang et al. (2018) showed the most promising results, with high discriminative 31 
potential and study power.21 Another biomarker candidate, miR-483-5p, studied by Nagaraj et al. (2017), also 32 
revealed high discriminative potential for both AD and MCI, as well as statistically significant results in both 33 
pilot and verification studies.24 This study, however, was limited by the small sample size and consequently, 34 
low study power. The other miRNA studies, which presented statistically significant results, either failed to 35 
investigate discriminative potential or had low statistical power.  36 
 37 
Autoantibodies are another area of focus when looking for non-invasive blood-based biomarker candidates for 38 
AD. The study by McIntyre et al. (2015) identified redox reactive antiphospholipid antibodies as serum 39 
autoantibodies detectable upon exposure to oxidizing agents, and potential biomarkers of early AD.26 A 40 
limitation of the study lied in the redox reactive oxidizing reagents required for detection, due to cost and 41 
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limited availability of reagent in different areas. Nevertheless, there is increased ability to generalize the 1 
technique to patients having early and late LOAD, due to inclusion of MCI patients in the sample. The 2 
resulting discriminative potential was also quite high for MCI patients. Giil et al. (2015) studied anti-ATR1 as a 3 
biomarker candidate, which yielded statistically significant differences in antibody levels for mild AD patients.27 4 
The utility of this biomarker can be severely limited, as the significant results were only applicable to patients 5 
without hypertension or diabetes, two highly prevalent systemic diseases. Future steps in evaluating 6 
autoantibodies include performing studies on a larger scale to increase statistical power and checking for 7 
accuracy of discriminating values. 8 
 9 
Preische et al. (2019) conducted an extensive study on serum NfL in relation to the onset and progression of 10 
AD.28 Longitudinal analysis of rates of change in serum NfL yielded significant elevations in subclasses of 11 
carriers of mutations in APP, PSEN1 or PSEN2 genes, which contribute to the heritability of EOAD.38,39 The 12 
strong association between NfL changes in CSF and blood is indicative of blood-based NfL changes reflecting 13 
changes in the brain in AD.40 The significant association between serum NfL rates of change and rates of 14 
precuneus cortical thinning is a noteworthy finding, since this area has been shown to be most sensitive to AD 15 
progression.41,42 The study results coupled with high statistical power show that longitudinal measures of 16 
serum NfL are a relatively cheap, non-invasive and reliable method of evaluating neurodegeneration and 17 
clinical progression. Future direction for longitudinal NfL studies warrants closer follow-up intervals to 18 
determine the association between the time period of rate of change and clinical predictability. Future work 19 
should also address translation of these findings to sporadic AD. 20 
 21 
Another promising blood-based protein studied was BACE1, which showed statistically significant increases in 22 
activity in AD patients, and those with MCI who eventually converted to AD.31 With a larger sample, the study 23 
had relatively high statistical power, and was also highly generalizable since patient groups were recruited 24 
from different populations in multiple countries. ACE activity was also similarly studied in a large population 25 
but revealed no statistically significant differences between MCI patients and controls. Nevertheless, the study 26 
reported significant data and utility of ACE activity pertaining to progression from MCI to AD.32 NP1, keratin 27 
type-2 and albumin had significantly different levels in MCI patients compared to controls, but discriminative 28 
potential of these biomarkers was not investigated and the studies had low statistical power and poor 29 
generalizability.29,30 Future studies warrant replication in larger, more representative study samples for 30 
validation of results. 31 
 32 
The studies investigating sEPCR and Gal-3 showed statistically significant differences in levels of each serum 33 
protein for AD patients, but there were no significant differences between MCI patients and controls.33,34 34 
Further study is warranted in larger study samples to validate these results and determine discriminative 35 
potential. Pai et al. (2018) reported significantly elevated CNA concentrations in patients with MCI compared 36 
to controls, but the study had low statistical power.36 The marker may show promise but warrants future work 37 
in larger MCI patient samples and investigation of discriminative potential for MCI patients specifically.  38 
 39 
Brain tissues from AD patients are noted to have abnormal expression of insulin receptors, as well as an 40 
alteration in the phosphorylation pattern of IRS-1, as is seen in patients with type II diabetes mellitus.43 41 
International Journal of Medical Students – Review. 
9 
IJMS 
Kapogiannis et al. (2014) investigated differential phosphorylation of the serine and tyrosine type-1 insulin 1 
receptor substrate (IRS-1) secondary to insulin resistance and reported statistically significant differences in 2 
these proteins in MCI as well as AD patients, as compared to controls.35 Furthermore, significant longitudinal 3 
study findings supported this biomarker candidate’s ability to accurately predict AD development, up to 10 4 
years prior to onset of clinical symptoms. The power of the study was a significant limitation due to the low 5 
sample size. Future work with IRS-1 should focus on replication in larger study samples, with a focus on 6 
subjects with MCI and determination of discriminative potential when differentiating MCI from controls.  7 
 8 
This review summarizes sixteen journal articles investigating various novel biomarkers potentially capable of 9 
aiding in the earlier diagnosis of AD. The studies were conducted in several different countries, giving a global 10 
perspective on the issue, but several studies had low statistical power due to relatively small sample sizes. 11 
Nevertheless, certain biomarkers such as NfL, BACE1 activity and the panel of miR-135a/193b/384 showed 12 
promising results with high relevance towards development of a non-invasive, clinically applicable AD 13 
diagnostic biomarker. 14 
 15 
The articles included in this study were limited to publications in English, which may have potentially excluded 16 
important and relevant manuscripts pertinent to the topic. Additionally, several reviewed articles used study 17 
samples from specific populations, leading to selection bias. Another limitation includes one database being 18 
used to search and identify publications relevant to the topic. The search was conducted by one investigator 19 
and selection of relevant articles depended on a single investigator’s judgement, potentially allowing for 20 
selection and reporting bias.  21 
 22 
Conclusion 23 
The blood-based biomarkers for an earlier AD diagnosis presented in this review encompassed microRNAs, 24 
autoantibodies, other proteins and circulating nucleic acids. Some of the novel biomarkers reviewed will 25 
require future studies for validation of results in larger study samples, or for determination of discriminative 26 
values. Further work, in terms of validation of these study results in larger samples and careful evaluation of 27 
the diagnostic technique, is warranted to identify the strongest diagnostic biomarkers with high potential and 28 
applicability to a clinical setting. A combinatorial approach is also possible and should be considered. Certain 29 
biomarkers – such as NfL, BACE1 activity and the panel of miR-135a/193b/384 – have shown promising 30 
results with high sensitivity and specificity, high discriminative potential for early AD (MCI patients vs. control 31 
subjects) and valid, statistically significant results. Utilization of such biomarkers will increase the efficacy of 32 
making an early clinical diagnosis of Alzheimer’s disease and begin interventions sooner. Such interventions 33 
could potentially reduce disability, delay severe disability, and enhance patients’ quality of life. 34 
35 
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FIGURES AND TABLES. 1 
 2 
Table 1. MicroRNA biomarkers for Alzheimer’s disease. 3 
 4 
Author, Title, Objective Study Sample,  Selection Criteria Methods Key Findings 
Yang et al. (2018) 
 
The Serum Exosome 
Derived MicroRNA-135a, -




Objective: To explore the 
potential value of serum 
exosomal microRNAs as 
biomarkers for diagnosing 
AD. 
107 AD; 101 MCI; 228 
controls 
 
Patients admitted to 
Xuanwu Hospital of Capital 
Medical University (Beijing, 
China) between September 
2015 and December 2016 
were enrolled in the study. 
 
Serum levels of three 
exosomal miRNAs (miR-
135a, miR-193b and miR-
384) were measured 
through exosome isolation, 
Western blotting and qRT-
PCR analysis. 
Serum miR-135a level 
Compared to controls: 
Significantly increased in AD 
(P < 0.05) 
Significantly increased in 
MCI (P < 0.05) 
 
Serum miR-193b level 
Compared to controls: 
Significantly reduced in AD 
(P < 0.01) 
Significantly reduced in MCI 
(P < 0.05) 
 
Serum miR-384 level 
Compared to MCI: 
Significantly higher in AD (P 
< 0.05) 
Significantly lower in controls 
(P < 0.05) 
 
Kumar et al. (2017) 
 
MicroRNA-455-3p as a 
potential peripheral 
biomarker for Alzheimer’s 
disease. 
 
Objective: To identify 
microRNAs as early 
detectable peripheral 
biomarkers in AD. 
 
10 AD; 16 MCI; 14 controls 
 
Sera and DNA samples 
obtained from patients 
under the FRONTIERS 
project (Texas Tech 
University Health Sciences 
Center). 
 
Inclusion criteria: Age ≥ 45 
years; rural community-
based West Texas 
individuals; assessed for 
cognitive functions. 
 
Exclusion criteria: On 
strong medications; many 
health complications 
 
After miRNA extraction, 
primary screening was 
performed by microarray 
analysis. Differentially 
expressed miRNAs were 
validated by qRT-PCR. 
 
miRNA data was further 
validated by using AD 
postmortem brains. 
miR-455-3p expression 
Compared to controls: 
Significantly upregulated in 
AD (P = 0.007) 
 
miR-4668-5p expression 
Compared to controls:  
Significantly upregulated in 
MCI (P = 0.016) 
 
Postmortem AD brains 
Significant upregulation of 
miR-455-3p (P = 0.016) 
Zeng et al. (2017) 
 
Expression of 
microRNA‑222 in serum of 
patients with Alzheimer's 
disease. 
 
Objective: To determine the 
association between AD 
and serum microRNA-222 
in patients with AD. 
 
30 moderate AD; 30 mild 
AD; 30 controls 
 
Patients were categorized 
into groups according to 
MMSE: mild (15< MMSE 
≤26) and moderate (10≤ 
MMSE ≤15) 
 
Exclusion criteria: History of 
cerebral vascular disease; 
TBI; toxic/metabolic/other 
brain disorders; drug 
therapy prior to diagnosis; 
blood system disease; 
dementia by vascular or 
other causes; no signed 
informed consent. 
 
After miRNA extraction, 
primary screening was 
performed by microarray 
analysis. Differentially 
expressed miRNAs were 
validated by qRT-PCR. 
microRNA-222 expression 
 
Compared to controls: 
Significantly lower in mild AD 
(P < 0.05) 
 
Compared to controls: 
Significantly lower in 
moderate AD (P < 0.05) 
 
Compared to mild AD: 
Significantly lower in 
moderate AD (P < 0.05) 
Nagaraj et al. (2017) 
 
Profile of 6 microRNA in 
blood plasma distinguish 
20 AD; 15 MCI; 15 controls 
 
All study subjects were 
Caucasian individuals from 
The study sample was 
divided into two groups: a 
pilot experiment (20 
subjects) and a verification 
miR-483-5p level 
Compared to controls: 
Significantly increased in 
MCI (P < 0.01 in pilot; P < 
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early stage Alzheimer’s 
disease patients from non-
demented subjects. 
 
Objective: To investigate 
the utility of plasma 
microRNAs as biomarkers 
for detecting early AD.  
 
Poland. Blood samples 
were taken from patients 
enrolled in the Alzheimer’s 
ward of Central Clinical 
Hospital of the Ministry of 
Interior in Warsaw. 
 
experiment (30 subjects). 
 
After miRNA isolation, qRT-
PCR was performed for 
both experiments (179 
miRNAs for pilot and 15 
miRNAs for verification).  
 
0.001 in verification) 
 
miR-200a-3p level 
Compared to controls: 
Significantly increased in 
MCI (P < 0.01 in both pilot 
and verification) 
 
Dong et al. (2015) 
 
Serum MicroRNA Profiles 
Serve as Novel Biomarkers 
for the Diagnosis of 
Alzheimer’s Disease. 
 
Objective: To identify and 
validate the potential of 
circulating miRNAs as novel 
biomarkers for AD. 
127 AD; 30 MCI; 123 
controls 
 
Study subjects comprised 
of patients being treated at 
Shanghai Mental Health 
Center, Nanjing Brain 
Hospital and Guangxi 
Jiangbin Hospital. 
 
After miRNA extraction, 
quantification of miRNAs 
was performed by qRT-
PCR.  
miR-93 concentration 
Compared to controls: 




Compared to controls: 




Compared to controls: 
Significantly higher in MCI (P 
< 0.01) 
 
AD: Alzheimer’s Disease; MCI: Mild Cognitive Impairment; miRNA: microRNA; qRT-PCR: Quantitative Real Time Polymerase 1 
Chain Reaction; MMSE: Mini-Mental State Examination; TBI: Traumatic Brain Injury  2 
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Table 2.  Autoantibodies as biomarkers for Alzheimer’s disease. 1 
 2 
Author, Title, Objective Study Sample,  Selection Criteria Methods Key Findings 
McIntyre et al. (2015) 
 
Antiphospholipid 
autoantibodies as blood 
biomarkers for detection of 
early stage Alzheimer’s 
disease. 
 
Objective: To investigate 
redox-reactive 
antiphospholipid 
autoantibodies as a 
diagnostic tool for mild pre-
AD. 
30 AD; 30 MCI; 30 controls 
 
Coded serum samples 
assigned to the three study 
groups by the Alzheimer’s 
Disease Neuroimaging 
Initiative were used. 
  
aPLs dependent on 
plasma-protein binding 
before binding epitopes on 
PLs were designated as 
aPLd, and those directly to 
epitopes on PLs were 
designated as aPLi.  Four 
different types of R-RAA 
aPLs were quantified in 
each group using ELISA, 
each with dependent and 
independent subtypes: 
(aPSd and aPSi), (aCLd 
and aCLi), (aPCd and aPCi) 
and (aPEd and aPEi).  
 
Quantitative ELISA was run 
on coded serum samples 
and R-RAA aPL activity 
was expressed as the 
difference in optical density 
between buffer-controlled 
samples and those treated 
with hemin (a redox 
reactive reagent which 
would unmask the aPLs 
and allow their detection). 
 
Serum IgG R-RAA aPSd 
Compared to controls: 
Significantly elevated in MCI 
(P = 0.011) 
Serum IgG R-RAA aPEd 
Compared to controls: 
Significantly elevated in MCI 
(P = 0.005) 
 
Serum IgG R-RAA aPCi 
Compared to controls: 
Significantly elevated in MCI 
(P = 0.001) 
 
Giil et al. (2015) 
 
Autoantibodies Toward the 
Angiotensin 2 Type 1 
Receptor: A Novel 
Autoantibody in Alzheimer’s 
Disease. 
 
Objective: To investigate 
the association between 
anti-AT1R and AD, and to 
investigate the association 
between clinical/biomarker 
features of anti-ATR1 and 
AD. 
 
92 mild AD; 102 controls 
 
Study subjects were 
recruited from the Dementia 
Study in Western Norway 
during 2005-2007 from 
three participating hospitals. 
 
Exclusion criteria: acute 
delirium/confusion, terminal 
illness, recently diagnosed 




Measurement of serum 
anti-ATR1 antibodies was 
done in duplicates by using 
a solid-phase sandwich 
ELISA.  
 
Absorbance was measured 
using an ELISA plate 
reader.  
Serum anti-ATR1 level 
 
Compared to controls: 
Significantly higher in mild 
AD patients without 
hypertension (p = 0.04) 
 
Compared to controls: 
Significantly higher in mild 
AD patients without diabetes 
(p = 0.008) 
AD: Alzheimer’s Disease; MCI: Mild Cognitive Impairment; aPLs: anti-phospholipid antibodies; aPSd: anti-Phosphatidylserine-3 
dependent Antibody; aPEd: anti-Phosphatidylethanolamine-dependent Antibody; aPCi: anti-Phosphatidylcholine-independent 4 
Antibody; R-RAA: Redox-Reactive Auto-Antibodies; ELISA: Enzyme-Linked Immunosorbent Assay; anti-ATR1: anti-angiotensin 5 
2 type 1 receptor antibody 6 
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Table 3. Other blood-based protein biomarkers for Alzheimer’s Disease.  1 
 2 
Author, Title, Objective Study Sample,  Selection Criteria Methods Key Findings 









Objective: To demonstrate 
that NfL levels in CSF and 
serum are correlated with 
each other and are elevated 
at the presymptomatic 
stages of familial AD. 
 
243 mutation carriers; 162 
non-carriers 
 
DIAN Data and 
biospecimens were used in 
the study. DIAN participants 
were members of families 
carrying autosomal-
dominant mutations in APP, 
PSEN1 or PSEN2. Family 
members not carrying the 






was used to measure NfL in 
CSF and serum of 405 
participants at the initial 
visit. 
 
196 participants returned 
for another 1-5 visits over a 
median observation time of 
3 years from initial visit. 
Among these, mutation 
carriers were further 
subdivided into pre-
symptomatic (CDR=0 
across all visits), converter 
(initially CDR=0, and 
CDR>0 at subsequent 
visits) or symptomatic 
(CDR>0 across all visits). 
 
Serum NfL rates of change 
were determined for these 
participants. Additionally, 
regression analysis was 
performed between NfL 
rates of change and rates of 
change in brain imaging. 
 
Serum NfL rates of change 
 
Significantly elevated in pre-
symptomatic carriers 
compared to non-carriers (P 
= 0.000671) 
 
Significantly elevated in 
converters compared to: 
Non-carriers (P =  
3.05 x 10-7) and 
Pre-symptomatic mutation 
carriers (P = 0.00119) 
 
Significantly elevated in 
symptomatic mutation 
carriers compared to: 
Non-carriers (P =  
8.78 x 10-12) and 
Pre-symptomatic mutation 
carriers (P = 0.000151) 
 
 
Rates of precuneus cortical 
thinning  
Significantly associated with 
rate of change of serum NfL 
in symptomatic mutation 
carriers (P=0.018) 
 
Kumar et al. (2018) 
 
Proteomics based 
identification of differential 
plasma proteins and 
changes in white matter 
integrity as markers in early 
detection of mild cognitive 
impaired subjects at high 
risk of Alzheimer’s disease. 
 
Objective: To identify and 
quantify differentially 
regulated plasma proteins 






Inclusion criteria: Ability to 
converse in Hindi/English; 
age > 50; memory 
complaint for > 6 months; 
stable and controlled 
medical conditions such as 
HTN, DM, hyperlipidemia. 
 
Exclusion criteria: Having 
other neurological diseases 
(stroke, severe small vessel 
disease, any other systemic 
problem). 
2D-PAGE of plasma protein 
in MCI (n=50) and controls 
(n=50), and identification of 
differentially regulated 
proteins with MALDI-TOF 
and MS-MS. 
 
Western blotting for 
quantification of Keratin 2 
and Albumin expression in 
serum of MCI (n=12) vs 
controls (n=12). 
Serum expression of Keratin 
type-2 protein 
Significantly increased in 
MCI compared to controls (p 
≤ 0.001) 
 
Serum expression of 
Albumin 
Significantly decreased in 
MCI compared to controls (p 
≤ 0.01) 
Ma et al. (2018) 
 
Neuronal pentraxin 1: A 
synaptic-derived plasma 
biomarker in Alzheimer's 
disease. 
 
Objective: To evaluate NP1, 
a potential CNS-plasma 




33 MCI; 31 controls 
 
Human plasma samples 
were obtained from APOE- 
genotyped controls and 
patients from the ImaGene 
Study conducted through 
the UCLA Easton 
Alzheimer’s Center. 
Quantification of plasma 
NP1 by sandwich ELISA. 
Plasma NP1 level 
Compared to controls: 
Significantly higher in MCI (p 
< 0.05) 
Shen et al. (2018) 
 
Increased Plasma BACE1 
May Predict Conversion to 
Alzheimer’s Disease 
Dementia in Individuals 
With Mild Cognitive 
75 probable AD; 96 MCI; 53 
controls 
 
Study subjects were 
recruited from three 
independent international 
academic AD research 
Plasma BACE1 activity was 




Protein expression of 
BACE1 was assessed by 
Plasma BACE1 activity 
(Vmax) 
Compared to controls: 
Significantly increased by 
62.8% (p = 0.001) in MCI 
converters 
Significantly increased by 





Objective: To identify the 
presence of BACE1 activity 
and determine potential 
BACE1 activity alterations 
in subjects with MCI. 
 
centers and memory clinics 
(Munich, Sweden and 
USA). This included 
patients with cognitively 
stable MCI (non-converters) 
and those with MCI who 
converted to AD 
(converters). 
 




Compared to controls: 
Significantly increased in AD 
(p < 0.05) 
 
Zhuang et al. (2016) 
 
Angiotensin converting 




Objective: To determine 
serum activities of ACE as 
a marker in diagnosis of 
AD. 
59 moderate-severe AD; 19 
mild AD; 45 aMCI; 39 
controls 
 
Study subjects were 
recruited from patients 
enrolled in Qingdao 
Municipal Hospital and 
through advertisements at 
senior clubs (2013-2014).  
 
Exclusion criteria: non-AD 
dementia; severe CHF; 
severe liver or kidney 
disease; severe COPD; 
cancer; symptoms of 
depression/anxiety/OCD; 
taking ACEi, ARB or other 
medication that could 
influence cognition. 
ACE activity was measured 
by sandwich ELISA. 
Serum ACE activity 
 
Compared to aMCI: 
Significantly higher in AD, 
considering different stages 
altogether (P = 0.03) 
 
Compared to aMCI: 
Significantly higher in 
moderate-severe AD (P = 
0.02) 
 
Compared to controls: 
Significantly higher in AD, 
considering different stages 
altogether (P = 0.01) 
 
Compared to controls: 
Significantly higher in 
moderate-severe AD (P = 
0.01) 
 
Zhu et al. (2015) 
 
Serum sEPCR Levels Are 
Elevated in Patients With 
Alzheimer’s Disease. 
 
Objective: To examine 
serum sEPCR levels in 
patients with AD, MCI and 
controls, and to determine 
its association with the 
degree of cognitive 
impairment (measured by 
MMSE). 
 
45 AD; 36 MCI; 42 controls 
 
Study subjects were 
recruited from the 
Department of Gerontology 
at the Huangshi Central 
Hospital Affiliated to Hubei 
Polytechnic University. 
Serum sEPCR levels were 
measured by ELISA. 
Serum sEPCR level 
 
Compared to controls: 
Significantly higher in AD (P 
= 0.0005) 
 
Wang et al. (2015) 
 
Elevated Galectin-3 Levels 
in the Serum of Patients 
With Alzheimer’s Disease. 
 
Objective: To compare 
serum Gal-3 levels in 
patients with AD, MCI and 
controls, and to evaluate its 
association with the clinical 
features of the disease.  
 
41 AD; 32 MCI; 46 controls 
 
Study subjects were 
recruited from the 
Department of Neurology in 
Yuhuangding Hospital and 
Qilu hospital of Shandong 
University. 
Serum Gal-3 levels were 
measured by ELISA.  
Serum Gal-3 level 
 
Compared to controls: 
Significantly higher in AD (P 
= 0.017) 
Kapogiannis et al. (2014) 
 
Dysfunctionally 
phosphorylated type 1 
insulin receptor substrate in 
neural-derived blood 
exosomes of preclinical 
Alzheimer’s disease. 
 
Objective: To investigate 
IRS-1 and its 
phosphorylated forms in 
neurally derived plasma 
32 AD; 16 aMCI; 81 
controls 
 
Study subjects (aMCI, 
n=16; mild/moderate 
dementia, n=10) included 
identified patients who had 
donated blood once in the 
CRU-NIA of Harbor 
Hospital (Baltimore, MD) or 
at Jewish Home of San 
Francisco (San Francisco, 
CA). 
After isolation of exosomes 
from plasma, quantification 
of exosome proteins was 
performed by ELISA. 
P-S312-IRS-1 level 
Compared to controls: 




Compared to controls: 
Significantly lower in AD (P < 
0.0001) 
 
Insulin Resistance Index, R 
Compared to controls: 
Significantly higher in AD (P 
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For longitudinal studies, 22 
additional AD patients were 
identified, who had given 
blood twice at Mayo Clinic 
of University of Kentucky 
(first when cognitively 
normal, second when 




Longitudinal Analysis of R 
Accurately predicted 
development of AD up to 10 
years prior to symptom onset 
 1 
NfL: Neurofilament Light Chain; CSF: Cerebrospinal Fluid; AD: Alzheimer’s Disease; DIAN: Dominantly Inherited Alzheimer 2 
Network; APP: Amyloid Precursor Protein; PSEN1: Presenilin 1; PSEN2: Presenilin 2; CDR: Clinical Dementia Rating; MCI: Mild 3 
Cognitive Impairment; HTN: Hypertension; DM: Diabetes Mellitus; 2D-PAGE: Two-Dimensional Polyacrylamide Gel 4 
Electrophoresis; MALDI-TOF: Matrix Assisted Laser Desorption/Ionization Time of Flight; MS-MS: Mass Spectrometry; NP1: 5 
Neuronal Pentraxin 1; CNS: Central Nervous System; APOE: Apolipoprotein E; UCLA: University of California Los Angeles; 6 
ELISA: Enzyme-Linked Immunosorbent Assay; BACE1: Beta-Secretase 1; ACE: Angiotensin Converting Enzyme; aMCI: 7 
Amnestic Mild Cognitive Impairment; CHF: Congestive Heart Failure; COPD: Chronic Obstructive Pulmonary Disease; OCD: 8 
Obsessive-Compulsive Disorder; ACEi: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin II Receptor Blocker; 9 
sEPCR: Soluble Endothelial Protein C Receptor; MMSE: Mini-Mental State Examination; Gal-3: Galectin-3; IRS-1: Type 1 Insulin 10 
Receptor Substrate; CRU-NIA: Clinical Research Unit of the National Institute on Aging 11 
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Table 4. Circulating Nucleic Acids as biomarkers for Alzheimer’s disease. 1 
 2 
Author, Title, Objective Study Sample,  Selection Criteria Methods Key Findings 
Pai et al. (2018) 
 
The Role of Methylated 
Circulating Nucleic Acids as 
a Potential Biomarker in 
Alzheimer’s Disease. 
 
Objective: To explore the 
role of methylated CNAs as 
potential biomarkers for 
diagnosing AD. 
27 probable-AD; 9 controls 
 
Study subjects were 
recruited from National 
Cheng Kung University 
Hospital (cases) and 
outpatient clinics (controls).  
 
Exclusion criteria: Evidence 




CNAs were extracted using 
the QIAamp CNA Kit. 
Purified CNAs were 
quantified by qRT-PCR for 
the human β-globin gene.  
 
DNA methylation of the 
LHX2 gene was analyzed 
by pyrosequencing after 
performing genome-wide 




Compared to controls: 
Significantly higher in 
probable-AD group (p < 0.01) 
 
Peaked in probable-AD 
patients classified as mild 
cognitive impairment, by 
MMSE (p< 0.05) 
 
LHX2 methylation 
Compared to controls: 
Significantly higher 
methylation of CpG sites 1 
and 5 in probable-AD group. 
 
 3 
CNA: Circulating Nucleic Acid; AD: Alzheimer’s Disease; qRT-PCR: Quantitative Real Time Polymerase Chain Reaction; LHX2: 4 
LIM Homeobox 2; CpG: Cytosine-phosphate-Guanine 5 
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Table 5. Discriminative potential of novel biomarkers, quantified by measures of diagnostic accuracy 1 
 2 
Study Diagnostic marker 
Control vs AD Control vs MCI 
Sensitivity Specificity Sensitivity Specificity 
Yang et al. 
miR-135a, miR193b, miR-384 - - 99% 95% 
miR-135a - - 90% 95% 
miR-193b - - 78% 77% 
miR-384 - - 85% 90% 
Nagaraj et al. miR-483-5p (pilot study) 80.0% 100% 83% 100% 
 miR-483-5p (verification study) 92.0% 100% 87% 100% 
McIntyre et al. aPSd, aPEd and aPCi - - 80% 83.3% 
Shen et al. BACE1 activity 64 – 84%   86 – 88% 66 – 70% 86 – 88% 
Pai et al. CNA concentration 67% 89% - - 
Study Diagnostic marker 
Control vs  
presymptomatic MC 
Control vs  
symptomatic MC  
Sensitivity Specificity Sensitivity Specificity 
Preische et al. Serum NfL (baseline) 92.0% 14.0% 85.0% 75.0% 
 Serum NfL (rate of change) 58.0% 78.0% 82.0% 89.0% 
 3 
AD: Alzheimer’s Disease; MCI: Mild Cognitive Impairment; miR: microRNA; aPSd: anti-Phosphatidylserine-dependent Antibody; 4 
aPEd: anti-Phosphatidylethanolamine-dependent Antibody; aPCi: anti-Phosphatidylcholine-independent Antibody; BACE1: Beta-5 
Secretase 1; CNA: Circulating Nucleic Acid; NfL: Neurofilament Light Chain; MC: Mutation Carrier 6 
 7 
